Trial · NCT02914314
Results by group434
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 434
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Core Phase, Cohort 1, Age >=1 to <=6 Months: Perampanel | Participants with TEAEs | 3 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Core Phase, Cohort 2, Age >6 to <=12 Months: Perampanel | Participants with TEAEs | 5 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Core Phase, Cohort 3, Age >12 to <24 Months: Perampanel | Participants with TEAEs | 9 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Core Phase, Cohort 4, Age >=24 to <48 Months: Perampanel | Participants with TEAEs | 3 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Extension Phase, Cohort 1, Age >=1 to <=6 Months: Perampanel | Participants with TEAEs | 4 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Extension Phase, Cohort 2, Age >6 to <=12 Months: Perampanel | Participants with TEAEs | 5 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Extension Phase, Cohort 3, Age >12 to <24 Months: Perampanel | Participants with TEAEs | 8 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Extension Phase, Cohort 4, Age >=24 to <48 Months: Perampanel | Participants with TEAEs | 1 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Core Phase, Cohort 1, Age >=1 to <=6 Months: Perampanel | Participants with SAEs | 2 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Core Phase, Cohort 2, Age >6 to <=12 Months: Perampanel | Participants with SAEs | 1 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Core Phase, Cohort 3, Age >12 to <24 Months: Perampanel | Participants with SAEs | 2 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Core Phase, Cohort 4, Age >=24 to <48 Months: Perampanel | Participants with SAEs | 1 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Extension Phase, Cohort 1, Age >=1 to <=6 Months: Perampanel | Participants with SAEs | 3 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Extension Phase, Cohort 2, Age >6 to <=12 Months: Perampanel | Participants with SAEs | 1 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Extension Phase, Cohort 3, Age >12 to <24 Months: Perampanel | Participants with SAEs | 3 | Participants | |
| Core Phase and Extension Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Extension Phase, Cohort 4, Age >=24 to <48 Months: Perampanel | Participants with SAEs | 0 | Participants | |
| Core Phase and Extension Phase: Mean Change From Baseline in Hematology Laboratory Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, and Platelets | Core Phase, Cohort 1, Age >=1 to <=6 Months: Perampanel | Change in Basophils | 0.03 | Standard Deviation 0.058 | 10^9 cells/L |
| Core Phase and Extension Phase: Mean Change From Baseline in Hematology Laboratory Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, and Platelets | Core Phase, Cohort 2, Age >6 to <=12 Months: Perampanel | Change in Basophils | -0.02 | Standard Deviation 0.110 | 10^9 cells/L |
| Core Phase and Extension Phase: Mean Change From Baseline in Hematology Laboratory Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, and Platelets | Core Phase, Cohort 3, Age >12 to <24 Months: Perampanel | Change in Basophils | -0.06 | Standard Deviation 0.151 | 10^9 cells/L |
| Core Phase and Extension Phase: Mean Change From Baseline in Hematology Laboratory Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, and Platelets | Core Phase, Cohort 4, Age >=24 to <48 Months: Perampanel | Change in Basophils | 0.00 | Standard Deviation 0.000 | 10^9 cells/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02914314/results